Is Adocia S.A. (ADOC.PA) a Buy, Sell, or Hold?
PAR : ADOC.PA
Adocia S.A.
$3.96 EUR
-$0.04 (-0.95%)
- Volume
- 72.43K
- Average Volume
- 173.96K
- Market Capitalization
- $79.23M
- P/E Ratio
- -4.08
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $12.40
- Year Low
- $3.61
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.19
Company Overview
PAR
Olivier Soula
Biotechnology
Healthcare
ADOC.PA
82
FR
EUR
Liquidity Metrics
5.97
1.19
1.17
0.86
0.00
Sales & Valuation
$1.48M
53.71
52.08
-11.66
-0.35
Profitability
-$0.85
-$16.59M
-1124.81%
-1286.51%
-3796.57%
-58.31%
P/E Metrics
-4.08
0.07
0.07
Analyst Price Target & Rating
1/5
1 Analysts
%
Financial Health Scores
-1.46
5/9
$3.84M
$28.45M
$26.96M
-$26.09M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Bertrand Alluis | Head of the Analysis Department and Project Manager |
| Jeremy Benattar | Marketing & Strategy Director |
| Grégory Meiffren | Head of the Biology Department & Project Manager |
| Richard Charvet | Head of Chemistry Department & Project Manager |
| Mathieu-William Gilbert | Chief Operating Officer & Chief Financial Officer |
| Olivier Soula | Co-Founder, Chief Executive Officer & Director |
| Geraldine Favre Soula | Director of Human Resources |
| David Duracher | Head of the Pharmaceutical Development & Physical Chemistry Departments and Project Manager |
Poll Results
No votes yet today — be the first to share your view!
About Adocia S.A. (PAR:ADOC.PA) Stock
Adocia S.A. is a clinical-stage biotechnology firm that specializes in developing enhanced formulations of existing therapeutic proteins and peptides, primarily targeting diabetes and other metabolic disorders. The company leverages its unique BioChaperone technological platform, specifically designed to boost the performance of these therapeutic proteins. Its robust clinical pipeline showcases several advanced insulin formulations, including BioChaperone Lispro U100 and U200, which are ultra-rapid-acting versions of insulin lispro. Other key candidates are BioChaperone Combo, a blend of long-acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, which pairs prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous human glucagon formulation for manag ... ing hypoglycemia. M1Pram, a derivative combining insulin glargine and pramlintide, is also under clinical investigation. In its earlier preclinical development phases, Adocia is advancing bi-hormonal products such as BioChaperone AsPram, a combination of rapid insulin aspart and pramlintide, and BioChaperone Glargine Liraglutidea, a fixed-dose pairing of insulin glargine with a GLP-1 receptor analogue. The preclinical portfolio also extends to multihormonal therapies for obesity, featuring BioChaperone GluExe (glucagon and exenatide), PramExe (pramlintide and exenatide), and BioChaperone PramGluExe, a triple combination of pramlintide, glucagon, and exenatide. Adocia has established a strategic partnership with Tonghua Dongbao Pharmaceutical Co., Ltd. to facilitate the development and commercialization of BioChaperone Lispro and BioChaperone Combo in China, as well as selected markets in Asia and the Middle East. The company was founded in 2005 and is headquartered in Lyon, France.
Frequently Asked Questions
-
What is the current Adocia S.A. (ADOC.PA) stock price?
-
Adocia S.A.(PAR:ADOC.PA) stock price is $3.96 in the last trading session. During the trading session, ADOC.PA stock reached the peak price of $12.4 while $3.61 was the lowest point it dropped to. The percentage change in ADOC.PA stock occurred in the recent session was --0.95% while the dollar amount for the price change in ADOC.PA stock was -$0.04.
-
ADOC.PA's industry and sector of operation?
-
The PAR listed ADOC.PA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ADOC.PA?
-
Bertrand Alluis | Head of the Analysis Department and Project Manager
Jeremy Benattar | Marketing & Strategy Director
Grégory Meiffren | Head of the Biology Department & Project Manager
Richard Charvet | Head of Chemistry Department & Project Manager
Mathieu-William Gilbert | Chief Operating Officer & Chief Financial Officer -
How many employees does ADOC.PA have?
-
Number of ADOC.PA employees currently stands at 82. ADOC.PA operates from 115 Avenue Lacassagne, Lyon, AR 69003, FR.
-
Link for ADOC.PA official website?
-
Official Website of ADOC.PA is: https://www.adocia.com
-
How do I contact ADOC.PA?
-
ADOC.PA could be contacted at phone #33 4 72 61 06 10 and can also be accessed through its website. ADOC.PA operates from 115 Avenue Lacassagne, Lyon, AR 69003, FR.
-
How many shares of ADOC.PA are traded daily?
-
The average number of ADOC.PA shares traded daily for last 3 months was 173.96K.
-
What is the market cap of ADOC.PA currently?
-
The market value of ADOC.PA currently stands at $79.23M with its latest stock price at $3.96